Increasing Transparency in Generic Drug Applications Act
This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).
| Action Date | Type | Text | Source |
|---|---|---|---|
| 2022-05-26 | IntroReferral | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. | Senate |
| 2022-05-26 | IntroReferral | Introduced in Senate | Library of Congress |